EMDR therapy for chemotherapy-induced conditioned nausea and vomiting in cancer survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study will deliver Eye Movement Desensitization and Reprocessing (EMDR) therapy to adult cancer survivors who report persistent conditioned nausea and/or vomiting after systemic chemotherapy. Participants will receive a course of EMDR sessions at the University Medical Center Groningen and symptom severity will be measured before, immediately after, and at follow-up visits. The trial excludes people with ongoing psychiatric treatment, dissociative or personality disorders, complex type 2 trauma, severe somatic conditions, pregnancy, or substance abuse that could cause nausea. Results will compare symptom change to characterize whether EMDR reduces conditioned nausea and vomiting in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Previously pathologically confirmed diagnosis of cancer
* Previously treated with systemic cancer therapy
* Persistent complaints (more than 2 months) of conditioned nausea and/or vomiting
* Able to understand spoken and written Dutch
* 18 years or older

Exclusion Criteria:

* Ongoing psychiatric treatment
* EMDR therapy contraindications (dissociative disorders, personality disorders or severe somatic disorders (e.g. cardiac arrhythmias))
* Complex type 2 trauma
* Known with recent conditions / non-anti-cancer medication which can elicit nausea (e.g. pregnancy or alcohol abuses)

Where it's running

• University Medical Center Groningen
  Groningen, Provincie Groningen, Netherlands Recruiting

Study contacts

• Principal investigator: Jacco J de Haan, MD, PhD — University Medical Center Groningen
• Study coordinator: Jacco J de Haan, MD, PhD
• Email: j.j.de.haan@umcg.nl
• Phone: +31503616161

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brief Behavioral Activation for cancer survivors 65+

  This study tests whether a short behavioral-activation therapy delivered by phone or video can help reduce depression and anxiety and improve well-being in English- or Spanish-speaking cancer survivors aged 65 and older.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07768449

• Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines

  This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.

  Recruiting at 2 sites St. James's Hospital, Ireland · Dublin and 1 other locations · NCT07561957

• GI-102 plus GIB-7 to target immune aging and gut‑brain‑muscle health

  This trial tests whether combining GI-102 and the synbiotic GIB-7 can improve aging-related biomarkers in healthy adults and cancer survivors.

  Recruiting at 2 sites Phase 2 GI Innovation, Inc. · Charlestown, New South Wales and 1 other locations · NCT07363057

• Relaxation and stress-reduction using yoga or mindfulness for cancer survivors

  This study will test whether oncology-informed yoga or SMART mindfulness training can improve well-being and change epigenetic markers in adult survivors of lung, colon, and non-Hodgkin's lymphoma cancers.

  Recruiting Stony Brook University · Stony Brook, New York · NCT07161713

• Italian employers' perspectives on supporting employees who return to work after cancer

  This project will talk with Italian employers to see how they manage and support employees returning to work after a cancer diagnosis.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia, RE · NCT06994182

• Social needs screening and connection program for Metro Detroit cancer survivors

  This project will test whether cancer survivors in Metro Detroit can complete a social needs screening and be connected to community resources for food and digital access.

  Recruiting Barbara Ann Karmanos Cancer Institute · Detroit, Michigan · NCT06908629

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.